Skip to main content
. 2021 Jan 8;9(1):52. doi: 10.3390/biomedicines9010052

Figure 5.

Figure 5

SIRT1 activation alleviates the cardiac dysfunction induced by endothelial cell-specific CRIF1 deletion. (a) Experimental treatment scheme. Mice were administered with SRT1720 (20 mg/kg) via intraperitoneal injection. twice per week from 4 to 9 week. (b) Line graph showing changes in body weight at weekly time points (4 to 9 weeks). (c) Heart weight and (d) heart/body weight of 9-week-old mice in WT, CRIF1 EKO, and CRIF1 EKO with SRT1720 treatment groups. (e) Representative whole mount hearts (top), H&E staining of the hearts of mice (Scale bar, 1 mm). (f) Representative M-mode echocardiograms and percentage of EF and FS determined from echocardiography. All data are presented as means ± SEM of at least three independent experiments (n = 4~7 mice in each group; * p < 0.05 vs. WT mice. # p< 0.05 vs. CRIF1 EKO mice).